Predict your next investment

Corporate Venture
HEALTHCARE | Pharmaceuticals / Drugs
baxalta.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Baxalta

Baxalta (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Company's therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation.

Baxalta Headquarter Location

1200 Lakeside Drive

Bannockburn, Illinois, 60015,

United States

224-948-2000

Latest Baxalta News

Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors

Jul 12, 2021

July 12, 2021 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Rheos Medicines , a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine (MetPM) platform, today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S. to its board of directors. Dr. Davis is an experienced physician-scientist drug developer and biotechnology executive with deep expertise across platforms, technologies and a range of therapeutic areas, including leadership roles at Pfizer, Baxalta, Magenta Therapeutics, and Genentech. “We are pleased to welcome John to our board of directors,” said Barbara Fox, Ph.D., Chief Executive Officer of Rheos Medicines. “John brings extensive expertise in bridging translational research and designing and implementing clinical development programs to advance new medicines for autoimmune and inflammatory diseases, as well as the unique perspective of a physician-scientist who continues to work closely with patients suffering from these conditions. His breadth of experience will be invaluable as we prepare to advance our lead program into the clinic next year, and explore the full potential of our MetPM product engine to build a leading franchise of precision medicines for autoimmune and inflammatory diseases.” In his most recent role, Dr. Davis serves as Chief Medical Officer and Head of Research and Development at Magenta Therapeutics, a biotechnology company bringing innovative therapies to the field of stem cell transplants for patients with autoimmune diseases, genetic diseases, and blood cancers. Prior to joining Magenta, Dr. Davis was Senior Vice President and Head of Early Clinical Development at Pfizer and, before that, he served as Vice President and Global Therapeutic Area Head of Immunology at Baxalta and as Senior Group Director and Head of the Inflammation and Cardiovascular/Metabolism Group in the Early Clinical Development Group at Genentech. Earlier, Dr. Davis spent nearly 10 years on the faculty at the University of California, San Francisco, leading clinical research in autoimmune diseases and serving as Professor of Clinical Medicine until 2015. He continues to see patients, teach, and serve as volunteer faculty at the Boston VA Medical Center. Dr. Davis holds his M.D. from the University of Maryland and completed his training in internal medicine and rheumatology at the University of California, San Francisco. He continued training in clinical research and rheumatology at the National Institutes of Health NIAMS intramural program. He holds an M.P.H. in Epidemiology from the University of California, Berkeley, and an M.S. in Anatomical Science from the University of Maryland School of Medicine. Dr. Davis is also a Fellow of the American College of Physicians and the American College of Rheumatology. “I am excited to join Rheos’ board of directors and look forward to working with the company’s management team to advance their vision of delivering a new class of precision medicines to patients with immune-mediated diseases,” said Dr. Davis. “I believe Rheos’ platform, which combines a deep understanding of metabolic processes with analyses to identify drivers of disease heterogeneity among patient subpopulations, opens the potential to discover novel precision medicines for patients with autoimmune and inflammatory diseases.” About Rheos Medicines Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple “omic” datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Baxalta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Baxalta is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Rare Diseases

229 items

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Baxalta Patents

Baxalta has filed 254 patents.

The 3 most popular patent topics include:

  • Coagulation system
  • Clusters of differentiation
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2017

10/5/2021

Clusters of differentiation, Immunology, Autoimmune diseases, Immune system, Chromatography

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/8/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/5/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immunology, Autoimmune diseases, Immune system, Chromatography

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.